A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Wenxin Du¹, Zhimei Xia¹, Zebin Luo², Yichang Chen³, Shaowei Bing¹, Wei Wang¹, Xingya Zhang¹, Zhan Zhou³, Jingying Zhang², Ji Cao^{1

4}, Bo Yang^{1

4}, Qiaojun He^{1

4

5}, Xuejing Shao⁶, Xiaojun Xu⁷, Meidan Ying^{8

9

10

11}

Affiliations

¹ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
² Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China.
³ Innovation Institute for Artificial Intelligence in Medicine, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, 310018, Hangzhou, China.
⁴ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China.
⁵ Cancer Center, Zhejiang University, 310058, Hangzhou, China.
⁶ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. xjshao@zju.edu.cn.
⁷ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. xuxiaojun@zju.edu.cn.
⁸ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.
⁹ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. mying@zju.edu.cn.
¹⁰ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China. mying@zju.edu.cn.
¹¹ Cancer Center, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.

PMID: 37714925
DOI: 10.1038/s41375-023-02024-6

Case Reports

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Wenxin Du et al. Leukemia. 2023 Nov.

. 2023 Nov;37(11):2286-2291.

doi: 10.1038/s41375-023-02024-6. Epub 2023 Sep 15.

Authors

Affiliations

¹ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
² Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China.
³ Innovation Institute for Artificial Intelligence in Medicine, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, 310018, Hangzhou, China.
⁴ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China.
⁵ Cancer Center, Zhejiang University, 310058, Hangzhou, China.
⁶ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. xjshao@zju.edu.cn.
⁷ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. xuxiaojun@zju.edu.cn.
⁸ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.
⁹ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. mying@zju.edu.cn.
¹⁰ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China. mying@zju.edu.cn.
¹¹ Cancer Center, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.

PMID: 37714925
DOI: 10.1038/s41375-023-02024-6

No abstract available

PubMed Disclaimer

Cited by

scTML: a pan-cancer single-cell landscape of multiple mutation types.
Li H, Ma T, Zhao Z, Chen Y, Xi X, Zhao X, Zhou X, Gao Y, Wei L, Zhang X. Li H, et al. Nucleic Acids Res. 2025 Jan 6;53(D1):D1547-D1556. doi: 10.1093/nar/gkae898. Nucleic Acids Res. 2025. PMID: 39420637 Free PMC article.
Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression.
Zhang X, Li M, Chen Y, Liu J, Zhang J, Shao C, Deng B, Zhang J, Wang T, Cao J, Xu X, He Q, Yang B, Shao X, Ying M. Zhang X, et al. Leukemia. 2025 Jul 24. doi: 10.1038/s41375-025-02698-0. Online ahead of print. Leukemia. 2025. PMID: 40707673

References

1. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118:3645–56. - DOI - PubMed
1. Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, et al. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia 2017;31:974–7. - DOI - PubMed
1. Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 2017;31:565–72. - DOI - PubMed
1. Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, et al. AML classification in the year 2023: How to avoid a Babylonian confusion of languages. Leukemia 2023;37:1413–20. - DOI - PubMed - PMC
1. Chen X, Wang F, Zhang Y, Ma XL, Cao PX, Yuan LL, et al. Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center. Blood Cancer J. 2021;11:112. - DOI - PubMed - PMC

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

82273942/National Natural Science Foundation of China (National Science Foundation of China)

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Affiliations

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical